Milioli Heloisa Helena
Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; School of Environmental & Life Science, The University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; School of Environmental & Life Science, The University of Newcastle, Callaghan, NSW, Australia.
Future Sci OA. 2016 Jun 6;2(2):FSO128. doi: 10.4155/fsoa-2016-0033. eCollection 2016 Jun.
Heloisa received a BSc degree in Biological Sciences (2008) from the Universidade Federal de Santa Catarina (Brazil) and obtained a MSc degree in Genetics (2011) from Universidade Federal do Paraná (Brazil). In 2011 and 2012, she worked as a lecturer and tutor in the Department of Cell Biology, Embryology and Genetics (Universidade Federal de Santa Catarina). She moved to Australia in 2012 to obtain her PhD in Biological Sciences, with emphasis on Bioinformatics, from The University of Newcastle. Her doctoral work brings together new considerations in the breast cancer field by combining novel bioinformatics approaches with the study of intrinsic subtypes. She has been applying advanced methods and sophisticated algorithms in unconventional computer architecture for the molecular classification of breast cancer based on the genomic (single nucleotide polymorphisms, circulating nucleic acids and copy number variations) and transcriptomic (gene expression and miRNA) signatures. Fundamental research will allow her to identify biomarkers of use in translational medicine for the diagnosis, prognosis and disease management focused on group-based tailored therapies.
赫洛伊斯于2008年获得圣卡塔琳娜联邦大学（巴西）生物科学理学学士学位，并于2011年获得巴拉那联邦大学（巴西）遗传学硕士学位。2011年和2012年，她在细胞生物学、胚胎学与遗传学系（圣卡塔琳娜联邦大学）担任讲师和助教。2012年，她前往澳大利亚，在纽卡斯尔大学获得生物科学博士学位，重点研究生物信息学。她的博士工作通过将新颖的生物信息学方法与内在亚型研究相结合，为乳腺癌领域带来了新的思考。她一直在将先进的方法和复杂的算法应用于非常规计算机架构，用于基于基因组（单核苷酸多态性、循环核酸和拷贝数变异）和转录组（基因表达和微小RNA）特征对乳腺癌进行分子分类。基础研究将使她能够识别用于转化医学的生物标志物，用于以基于群体的定制疗法为重点的诊断、预后和疾病管理。
